

Freedom of Information Request	FOI 22-539	30 <sup>th</sup> November 2022
--------------------------------	------------	--------------------------------

**On July 13th, 2022, the National Institute for Health & Care Excellence (NICE) published their Single Technology Appraisal for our drug, Icosapent Ethyl, a new medicine into Chapter 2: Cardiovascular System in the lipid-regulating section of the British National Formulary (BNF), please find the link below**

[Project information | Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides \[ID3831\] | Guidance | NICE](#)

**In order that the eligible patients across your local health economy can benefit from the access to this medicine I believe that the drug will need to be locally reviewed through a 'formulary process'.**

**As per the rules pertaining to the Freedom of Information Act, I am writing to you to request the following information:**

- 1. The process(es) for drugs which have a NICE Technology Appraisal?**  
The Health Board manages Drugs which have a positive Final Appraisal Determination (FAD) through the High Cost Drugs Implementation Planning Group (HCDIPG). On publication of a FAD, the formulary pharmacist sends out an implementation form to the relevant clinical directorate. Clinicians, pharmacist and finance input to the plan is required. The plan is then reviewed by the HCDIPG who meet monthly. If the HCDIPG are satisfied with the implementation plan, the drug can be added to the formulary. Approval from clinical director, divisional/directorate pharmacist and divisional business partner accountant is required before the plan can be signed off. Once the HCDIPG has approved the plan, it goes on the formulary as Red (interim status) The Medicines and Therapeutics Committee then decide on the most appropriate traffic light status for the drug (Red, Amber or Green).
- 2. The name of the formulary committee(s) that will be reviewing this on behalf of your organisation?**  
High Cost Drug Implementation Planning Group (HCDIPG) and Medicines and Therapeutics Committee (MTC).
- 3. The forthcoming dates of these committee(s) meetings as far as they have been scheduled?**  
The next meeting is on 12<sup>th</sup> December 2022. The dates for 2023 have yet to be arranged.

**4. Name of the committee(s) Secretary and contact details?**

All enquires are sent to the following shared mailbox  
[GPMTTC@wales.nhs.uk](mailto:GPMTTC@wales.nhs.uk)

**5. Name of the committee(s) Chair and contact details?**

Jonathan Simms  
Clinical Director of Pharmacy  
[jonathan.simms@wales.nhs.uk](mailto:jonathan.simms@wales.nhs.uk)

**6. Copies of the previous two minutes from the committee(s) meetings?**

Please see attached copies of minutes of the last two committee meetings.

**7. Copy of the Terms of Reference for the committee(s)?**

Please see attached the terms of reference.

**8. Copy of the application form which needs to be completed, where a different form is applicable for different committees, please send over each one?**

Please see attached.

**NICE ask that this is completed within a 60-day window post the Health Technology Appraisal being published in England, this date being 11th September, 2022. This date has now passed and from what I can see on your publicly available local formulary website, this has not happened to date**

<http://aneurinbevanhb.inform.wales.nhs.uk/>

**For this reason, I am also writing to you to request the following information,**

**9. Has Icosapent Ethyl been reviewed?**

Icosapent Ethyl has now been reviewed and signed off by the Health Board

**10. if not, has Icosapent Ethyl been allocated as an agenda item on an upcoming committee(s) meeting?**

Not applicable.

**11. Name of the person who has completed the 'formulary paperwork' on behalf of the drug that will be shared with the committee(s)**

Dr Nadia El-Farhan, Consultant Chemical Pathologist.